id: NEW:immune_checkpoint_inhibitor_plus_chemotherapy_to_NEW:objective_response_rate_advanced_gej_cancer
name: Immune Checkpoint Inhibitor Plus Chemotherapy Treatment â†’ Objective Response Rate in Advanced Gastric/Gastroesophageal
  Junction Cancer
from_node:
  node_id: NEW:immune_checkpoint_inhibitor_plus_chemotherapy
  node_name: Immune Checkpoint Inhibitor Plus Chemotherapy Treatment
to_node:
  node_id: NEW:objective_response_rate_advanced_gej_cancer
  node_name: Objective Response Rate in Advanced Gastric/Gastroesophageal Junction Cancer
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: ICI therapy enhances T-cell mediated tumor cell killing'
- 'Step 2: Chemotherapy causes direct cytotoxic damage to tumor cells'
- 'Step 3: Combined treatment leads to greater tumor shrinkage'
- 'Step 4: Higher proportion of patients achieve partial or complete response'
- 'Step 5: Measurable tumor reduction documented on imaging (objective response)'
evidence:
  quality_rating: A
  n_studies: 5
  primary_citation: 'Lianghui Zhang et al. 2024. "Immune Checkpoint Inhibitor Plus Chemotherapy as First-Line
    Treatment for Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis."
    https://doi.org/10.1177/15330338241273286'
  supporting_citations:
  - Additional citations require full-text access - meta-analysis included 5 randomized controlled trials
  - Studies involving 2,814 patients with advanced G/GEJ cancer
  - Trials comparing ICI plus chemotherapy versus chemotherapy alone as first-line treatment
  doi: 10.1177/15330338241273286
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Combination of immune checkpoint inhibitors with chemotherapy as first-line treatment significantly
  improves objective response rate in patients with advanced gastric or gastroesophageal junction cancer
  compared to chemotherapy alone, with a 20% relative increase in response rate.
quantitative_effects:
  effect_size:
    value: 1.2
    type: relative_risk
    ci_lower: 1.11
    ci_upper: 1.3
  p_value: 0.001
  sample_size: 2814
structural_competency:
  equity_implications: Higher response rates may improve quality of life and symptom control. Access to
    combination immunotherapy requires specialized oncology infrastructure, which may be concentrated
    in urban academic medical centers, creating geographic disparities in treatment access and outcomes.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.898126'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
